Weight-loss drugs in India are set to become significantly cheaper as several pharmaceutical companies prepare to launch affordable generic versions of semaglutide, the key ingredient in popular medicines such as Wegovy and Ozempic. The price reduction comes after the semaglutide patent expires on March 20, allowing domestic drugmakers to enter the market with lower-cost alternatives.
Major Indian pharmaceutical companies, including Sun Pharma, Zydus Lifesciences, Dr. Reddy’s, and Natco Pharma, are expected to launch generic versions immediately after the patent expiry. More companies are likely to follow in the coming months, increasing competition and putting downward pressure on prices in India’s growing anti-obesity drug market.
Analysts estimate that generic semaglutide could be priced around ₹3,500 to 4,000 per month for initial doses, roughly 50% lower than the current branded option. Previously, blockbuster weight-loss drugs such as Wegovy were priced around ₹10,000 per month even after price reductions, making them expensive for many patients. Lower-cost alternatives are expected to make these treatments more accessible to a wider population.
India’s weight-loss drugs market, currently valued at around ₹1,400 crore, is expected to grow rapidly as prices fall and access improves. Experts believe increased competition will unlock.
Also Read: Amazon Unveils Second-Largest Asia Office in Bengaluru
Pharmaceutical companies are preparing for strong demand by expanding their production and distribution networks. Sun Pharma, for example, plans to launch generic semaglutide in user-friendly prefilled pen formats and ensure sufficient supply nationwide. Companies are also investing in partnerships and expanding field operations to strengthen their market presence.
The entry of affordable generic versions is expected to transform India’s weight-loss drug market by improving affordability, increasing treatment access, and accelerating growth. This shift could also position India as a major supplier of cost-effective obesity treatment in global markets.
